Concepts (221)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 15 | 2025 | 447 | 3.270 |
Why?
|
| Osteosarcoma | 12 | 2024 | 263 | 2.250 |
Why?
|
| Sarcoma, Ewing | 4 | 2025 | 117 | 1.290 |
Why?
|
| Hematuria | 1 | 2025 | 55 | 0.910 |
Why?
|
| Antineoplastic Agents | 7 | 2025 | 1850 | 0.790 |
Why?
|
| Hypersplenism | 1 | 2020 | 2 | 0.700 |
Why?
|
| Desmoplastic Small Round Cell Tumor | 1 | 2020 | 12 | 0.690 |
Why?
|
| Disclosure | 1 | 2021 | 154 | 0.660 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2019 | 23 | 0.610 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 235 | 0.590 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2025 | 1354 | 0.580 |
Why?
|
| Embolization, Therapeutic | 1 | 2020 | 224 | 0.570 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2018 | 12 | 0.570 |
Why?
|
| Neoplasms | 6 | 2025 | 3025 | 0.550 |
Why?
|
| Acute Kidney Injury | 1 | 2025 | 686 | 0.550 |
Why?
|
| Retinal Neoplasms | 1 | 2018 | 104 | 0.520 |
Why?
|
| Wilms Tumor | 1 | 2018 | 119 | 0.520 |
Why?
|
| Lung Neoplasms | 4 | 2019 | 1789 | 0.500 |
Why?
|
| Hepatoblastoma | 1 | 2018 | 184 | 0.480 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2021 | 1006 | 0.430 |
Why?
|
| Neuroblastoma | 1 | 2019 | 539 | 0.420 |
Why?
|
| Kidney Neoplasms | 1 | 2018 | 463 | 0.420 |
Why?
|
| RNA, Long Noncoding | 3 | 2022 | 246 | 0.410 |
Why?
|
| Ifosfamide | 2 | 2025 | 35 | 0.410 |
Why?
|
| Rhabdomyosarcoma | 3 | 2021 | 209 | 0.400 |
Why?
|
| Receptor, ErbB-2 | 3 | 2015 | 559 | 0.390 |
Why?
|
| T-Lymphocytes | 4 | 2017 | 1814 | 0.390 |
Why?
|
| Neoplasm Metastasis | 5 | 2024 | 746 | 0.380 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2025 | 884 | 0.370 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 1409 | 0.360 |
Why?
|
| Neoplasms, Experimental | 1 | 2011 | 226 | 0.340 |
Why?
|
| Child | 19 | 2025 | 25712 | 0.340 |
Why?
|
| Cancer Survivors | 3 | 2025 | 247 | 0.310 |
Why?
|
| Neoplastic Stem Cells | 1 | 2011 | 352 | 0.300 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2022 | 381 | 0.290 |
Why?
|
| Humans | 34 | 2025 | 133849 | 0.270 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 1410 | 0.270 |
Why?
|
| Adolescent | 14 | 2025 | 20517 | 0.250 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2024 | 2122 | 0.250 |
Why?
|
| Immunotherapy | 3 | 2017 | 747 | 0.240 |
Why?
|
| Basal Cell Nevus Syndrome | 1 | 2025 | 15 | 0.240 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2025 | 34 | 0.240 |
Why?
|
| Gene Expression Profiling | 2 | 2015 | 1911 | 0.230 |
Why?
|
| Pericardial Effusion | 1 | 2025 | 71 | 0.230 |
Why?
|
| Anthracyclines | 2 | 2025 | 44 | 0.230 |
Why?
|
| Mice, SCID | 4 | 2019 | 613 | 0.230 |
Why?
|
| Methotrexate | 2 | 2019 | 355 | 0.220 |
Why?
|
| Mice, Inbred NOD | 3 | 2019 | 318 | 0.210 |
Why?
|
| Tripartite Motif-Containing Protein 28 | 1 | 2022 | 16 | 0.200 |
Why?
|
| MicroRNAs | 2 | 2023 | 951 | 0.190 |
Why?
|
| Proton Therapy | 1 | 2024 | 151 | 0.190 |
Why?
|
| Cardiovascular Diseases | 2 | 2025 | 2082 | 0.190 |
Why?
|
| Sertoli-Leydig Cell Tumor | 1 | 2022 | 17 | 0.190 |
Why?
|
| Electron Transport Complex I | 1 | 2021 | 34 | 0.190 |
Why?
|
| Rothmund-Thomson Syndrome | 1 | 2021 | 47 | 0.180 |
Why?
|
| Cell Line, Tumor | 5 | 2024 | 3751 | 0.180 |
Why?
|
| Hematologic Neoplasms | 1 | 2025 | 294 | 0.180 |
Why?
|
| RecQ Helicases | 1 | 2021 | 64 | 0.180 |
Why?
|
| MyoD Protein | 1 | 2021 | 26 | 0.180 |
Why?
|
| Stroke Volume | 2 | 2022 | 530 | 0.180 |
Why?
|
| Doxorubicin | 2 | 2020 | 302 | 0.180 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2019 | 820 | 0.180 |
Why?
|
| Ribonuclease III | 1 | 2022 | 103 | 0.180 |
Why?
|
| Acrylamides | 1 | 2020 | 25 | 0.170 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2022 | 147 | 0.170 |
Why?
|
| Uncertainty | 1 | 2021 | 105 | 0.170 |
Why?
|
| Atrial Function, Left | 1 | 2020 | 29 | 0.170 |
Why?
|
| Ventricular Function, Left | 2 | 2022 | 541 | 0.170 |
Why?
|
| p21-Activated Kinases | 1 | 2020 | 58 | 0.170 |
Why?
|
| Aminopyridines | 1 | 2020 | 60 | 0.170 |
Why?
|
| Etoposide | 1 | 2020 | 120 | 0.170 |
Why?
|
| ras Proteins | 1 | 2020 | 146 | 0.160 |
Why?
|
| Echocardiography, Doppler | 1 | 2020 | 173 | 0.160 |
Why?
|
| Vincristine | 1 | 2020 | 196 | 0.160 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2021 | 128 | 0.160 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2019 | 45 | 0.160 |
Why?
|
| Mice | 11 | 2024 | 18883 | 0.160 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2020 | 136 | 0.160 |
Why?
|
| Cell Proliferation | 6 | 2024 | 2539 | 0.160 |
Why?
|
| Pyrroles | 1 | 2020 | 187 | 0.160 |
Why?
|
| Epigenesis, Genetic | 1 | 2024 | 773 | 0.150 |
Why?
|
| Biomarkers, Tumor | 4 | 2020 | 1717 | 0.150 |
Why?
|
| Radiation Injuries | 1 | 2020 | 165 | 0.150 |
Why?
|
| Infant | 5 | 2025 | 13135 | 0.150 |
Why?
|
| Prognosis | 4 | 2025 | 5070 | 0.150 |
Why?
|
| Cyclophosphamide | 1 | 2020 | 418 | 0.150 |
Why?
|
| beta Catenin | 1 | 2019 | 229 | 0.140 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2019 | 197 | 0.140 |
Why?
|
| Female | 16 | 2025 | 71584 | 0.140 |
Why?
|
| Pyrazoles | 1 | 2020 | 328 | 0.140 |
Why?
|
| Heart Atria | 1 | 2020 | 333 | 0.140 |
Why?
|
| Follow-Up Studies | 4 | 2025 | 5505 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 1314 | 0.140 |
Why?
|
| Ovarian Neoplasms | 1 | 2022 | 464 | 0.140 |
Why?
|
| Skin Neoplasms | 1 | 2025 | 906 | 0.140 |
Why?
|
| Cardiomyopathies | 1 | 2022 | 514 | 0.140 |
Why?
|
| Bone Marrow | 1 | 2019 | 334 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2025 | 1188 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2017 | 501 | 0.130 |
Why?
|
| Bone and Bones | 1 | 2019 | 310 | 0.130 |
Why?
|
| Male | 15 | 2025 | 65815 | 0.130 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2017 | 170 | 0.130 |
Why?
|
| Neoplasm Staging | 3 | 2017 | 1386 | 0.130 |
Why?
|
| Sarcoma, Experimental | 1 | 2015 | 16 | 0.120 |
Why?
|
| Heart Diseases | 1 | 2020 | 522 | 0.120 |
Why?
|
| Treatment Outcome | 6 | 2024 | 13011 | 0.120 |
Why?
|
| Receptors, Cell Surface | 1 | 2017 | 494 | 0.120 |
Why?
|
| Animals | 11 | 2024 | 36363 | 0.120 |
Why?
|
| Young Adult | 6 | 2025 | 9885 | 0.120 |
Why?
|
| Heart Transplantation | 1 | 2022 | 894 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1315 | 0.120 |
Why?
|
| Biopsy | 1 | 2019 | 1304 | 0.120 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2015 | 168 | 0.110 |
Why?
|
| Echocardiography | 1 | 2020 | 1111 | 0.110 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2017 | 266 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 217 | 0.110 |
Why?
|
| Parents | 1 | 2021 | 1058 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 3 | 2020 | 1102 | 0.100 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 717 | 0.100 |
Why?
|
| Heart-Assist Devices | 1 | 2022 | 1093 | 0.100 |
Why?
|
| Cardiotoxicity | 2 | 2025 | 39 | 0.100 |
Why?
|
| Receptor, EphA2 | 1 | 2012 | 29 | 0.100 |
Why?
|
| Sarcoma | 1 | 2015 | 210 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2015 | 1070 | 0.100 |
Why?
|
| Radiotherapy | 2 | 2025 | 148 | 0.090 |
Why?
|
| Retrospective Studies | 7 | 2025 | 17456 | 0.090 |
Why?
|
| Organic Chemicals | 1 | 2011 | 60 | 0.090 |
Why?
|
| Luminescent Measurements | 1 | 2011 | 61 | 0.090 |
Why?
|
| Spheroids, Cellular | 1 | 2011 | 63 | 0.090 |
Why?
|
| Apoptosis | 4 | 2020 | 1931 | 0.090 |
Why?
|
| Predictive Value of Tests | 3 | 2022 | 2292 | 0.090 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2011 | 130 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2015 | 792 | 0.090 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 275 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 407 | 0.090 |
Why?
|
| Fluorescent Dyes | 1 | 2011 | 270 | 0.080 |
Why?
|
| Child, Preschool | 5 | 2025 | 14776 | 0.080 |
Why?
|
| Pediatrics | 1 | 2018 | 1216 | 0.080 |
Why?
|
| HEK293 Cells | 1 | 2011 | 813 | 0.080 |
Why?
|
| Heart Failure | 1 | 2022 | 2416 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 1326 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 1153 | 0.070 |
Why?
|
| Glioblastoma | 1 | 2012 | 375 | 0.070 |
Why?
|
| Mutation | 4 | 2025 | 6289 | 0.070 |
Why?
|
| Adult | 4 | 2018 | 31925 | 0.070 |
Why?
|
| Risk Factors | 4 | 2025 | 11077 | 0.070 |
Why?
|
| Transcriptome | 1 | 2015 | 1126 | 0.070 |
Why?
|
| Osteoblasts | 2 | 2021 | 164 | 0.070 |
Why?
|
| Genetic Therapy | 1 | 2012 | 733 | 0.070 |
Why?
|
| Patched-1 Receptor | 1 | 2025 | 50 | 0.060 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2023 | 22 | 0.050 |
Why?
|
| Radiotherapy Dosage | 1 | 2024 | 231 | 0.050 |
Why?
|
| American Heart Association | 1 | 2025 | 328 | 0.050 |
Why?
|
| Survival Rate | 2 | 2017 | 2207 | 0.050 |
Why?
|
| Cell Respiration | 1 | 2021 | 24 | 0.050 |
Why?
|
| Oxadiazoles | 1 | 2021 | 25 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2020 | 3638 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2021 | 93 | 0.050 |
Why?
|
| Oxidative Phosphorylation | 1 | 2021 | 124 | 0.040 |
Why?
|
| Chromatin | 1 | 2024 | 609 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 2021 | 295 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 3050 | 0.040 |
Why?
|
| Osteogenesis | 1 | 2021 | 167 | 0.040 |
Why?
|
| Consensus | 1 | 2024 | 739 | 0.040 |
Why?
|
| Quinolines | 1 | 2021 | 112 | 0.040 |
Why?
|
| Cellular Senescence | 1 | 2021 | 201 | 0.040 |
Why?
|
| Systole | 1 | 2020 | 206 | 0.040 |
Why?
|
| Imidazoles | 1 | 2021 | 217 | 0.040 |
Why?
|
| Piperidines | 1 | 2021 | 239 | 0.040 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2021 | 232 | 0.040 |
Why?
|
| Observer Variation | 1 | 2020 | 312 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 689 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2022 | 1488 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 455 | 0.040 |
Why?
|
| Incidence | 1 | 2025 | 3393 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2021 | 1046 | 0.030 |
Why?
|
| Cell Movement | 1 | 2020 | 917 | 0.030 |
Why?
|
| Texas | 1 | 2025 | 3684 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2019 | 607 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2020 | 573 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 290 | 0.030 |
Why?
|
| Caspase 2 | 1 | 2015 | 28 | 0.030 |
Why?
|
| Neuroectodermal Tumors | 1 | 2015 | 13 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2015 | 110 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 971 | 0.030 |
Why?
|
| Karyotyping | 1 | 2015 | 324 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 173 | 0.030 |
Why?
|
| Gene Amplification | 1 | 2015 | 247 | 0.030 |
Why?
|
| Allografts | 1 | 2015 | 197 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2025 | 3476 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2015 | 244 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2015 | 366 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2015 | 791 | 0.030 |
Why?
|
| Homozygote | 1 | 2015 | 560 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 2975 | 0.030 |
Why?
|
| ROC Curve | 1 | 2015 | 615 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 310 | 0.030 |
Why?
|
| Genomics | 1 | 2021 | 1676 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2024 | 6655 | 0.030 |
Why?
|
| K562 Cells | 1 | 2012 | 100 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2015 | 905 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 2015 | 664 | 0.020 |
Why?
|
| Retroviridae | 1 | 2012 | 198 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 1139 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2012 | 250 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2012 | 296 | 0.020 |
Why?
|
| Adoptive Transfer | 1 | 2012 | 241 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 3738 | 0.020 |
Why?
|
| Recurrence | 1 | 2015 | 1467 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2015 | 927 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2012 | 538 | 0.020 |
Why?
|
| Time Factors | 1 | 2020 | 6584 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2022 | 4896 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2015 | 2527 | 0.020 |
Why?
|
| United States | 1 | 2025 | 11682 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2012 | 970 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 2196 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2015 | 3969 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 4800 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 4772 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 3843 | 0.010 |
Why?
|